SCHEMBL2853973

SCHEMBL2853973

N[C@@H](CCCCN1CCN(c2nc3ccccc3s2)CC1)C(=O)N1CCSC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 5/20 0.49
NPC1 O15118 6/20 0.48
RAB9A P51151 6/20 0.48
MAPT P10636 2/20 0.48
LMNA P02545 1/20 0.48
DPP7 Q9UHL4 4/20 0.47
DPP8 Q6V1X1 2/20 0.47
DPP9 Q86TI2 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
CYP1A2 P05177 1/20 0.47
POLB P06746 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
MAPK1 P28482 1/20 0.46
HTR1A P08908 2/20 0.46
DRD2 P14416 2/20 0.46
HTR2A P28223 2/20 0.46
HTR7 P34969 2/20 0.46
USP2 O75604 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2853982 1.00 DPP4 (0.49) DPP4NPC1RAB9AMAPTLMNA
SCHEMBL2855953 0.88 NPC1 (0.53) DPP4NPC1RAB9AMAPTDPP7
SCHEMBL2855956 0.88 NPC1 (0.53) DPP4NPC1RAB9AMAPTDPP7
SCHEMBL2855158 0.88 DPP4 (0.44) DPP4NPC1RAB9AMAPTDPP7
SCHEMBL2855154 0.88 DPP4 (0.44) DPP4NPC1RAB9AMAPTDPP7
SCHEMBL2851844 0.86 DPP4 (0.54) DPP4DPP7DPP8DPP9HTR1A
SCHEMBL2847982 0.86 DPP4 (0.46) DPP4NPC1RAB9AMAPTDPP7
SCHEMBL2855166 0.86 MAPT (0.43) DPP4RAB9AMAPTLMNADPP7
SCHEMBL2855160 0.86 MAPT (0.43) DPP4RAB9AMAPTLMNADPP7
SCHEMBL2847980 0.86 DPP4 (0.46) DPP4NPC1RAB9AMAPTDPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790725-B2 Thiazolidine derivatives and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-07 US disclosed
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2007-11-08 US disclosed
CN-1606549-A Thiazolidine derivative and medical application thereof MITSUBISHI PHARMA CORP (JP) 2005-04-13 CN disclosed
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-12-23 US disclosed
EP-1426366-A1 THIAZOLIDINE DERIVATIVE AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2004-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF DPP4, DPP7, DPP3 DPP4 1/4885NPC1 1300/4885RAB9A 3752/4885
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof DPP4, DPP7, DPP3 DPP4 1/4885NPC1 902/4885RAB9A 3841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.